Ozempic contains semaglutide, a GLP-1 receptor agonist that mimics the activity of the naturally occurring hormone glucagon-like peptide-1. It influences glucose-dependent insulin secretion, glucagon release, gastric emptying, and appetite regulation.
The medicine is used alongside diet and physical activity to improve blood glucose control in adults with type 2 diabetes and may provide cardiovascular risk-reduction benefits for certain eligible patients.
Gastrointestinal reactions such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort can occur. Treatment suitability depends on medical history, concurrent medicines, and individual risk factors.
Reviews
There are no reviews yet.